Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Paricalcitol as Pre-operative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas

NCT03138720 is registered in ClinicalTrials.gov with HonorHealth Research Institute as lead sponsor.

NCT NCT03138720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03138720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Paricalcitol as Pre-operative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas
Lead sponsor
HonorHealth Research Institute
Phase
Phase 2
Overall status
Completed
Start date
May 23, 2017
Completion date
November 3, 2025
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neoadjuvant pancreatic cancer, pancreatic adenocarcinoma, resectable pancreatic cancer, unresectable pancreatic cancer